

**REMARKS**

Claim 30 is amended to be dependent on claim 34, rather than canceled claim 17. New claims 40-43 are directed to further aspects of applicants' invention and are supported throughout applicants' disclosure. See, e.g., the disclosure at page 3, lines 10-18, page 6, lines 3-8, and the Examples.

Respectfully submitted,



Brion P. Heaney (Reg. No. 32,542)  
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington, Virginia 22201  
Direct Dial: (703) 812-5308  
Facsimile: (703) 243-6410  
Internet Address: [heaney@mwzb.com](mailto:heaney@mwzb.com)

Filed: May 14, 2000

BPH:imm\K:\Sch\1655\Prelim Amendment.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

**IN THE CLAIMS:**

Please amend claim 30 as follows:

**30.** A method according to claim 34 ~~17~~, wherein said LHRH analogue is administered in the amount of 2  $\mu$ g-20 mg per kilogram of body weight and said anti-estrogen is administered in an amount of 0.1  $\mu$ g-10 mg per kilogram of body weight.

Please add claims 40-42 as follows:

**40.** A method according to claim 34, wherein said LHRH analogue is Leuprorelin, Cetrorelix, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Zoladex, or Ramorelix.

**41.** A method according to claim 40, wherein anti-estrogen is Raloxifen, Droloxifen, or Centchroman.

**42.** A method according to claim 41, wherein said LHRH analogue is Antide and said anti-estrogen is Raloxifen.

**43.** A method according to claim 41, wherein said LHRH analogue is Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub> and said anti-estrogen is Droloxifen.